Lyrica (Pregabalin) molecular model
Numéro d’image : 12033639
| Lyrica (Pregabalin) ((S)-3-(aminomethyl)-5-methylhexanoic acid) was approved in 2007 by the U.S. Food and Drug Administration for the treatment of fibromyalgia. Until then,Pregabalin was used to treat diabetic peripheral neuropathy,post-herpetic neuralgia,and as an additional therapy for adults with partial onset seizures. Lyrica's mode of action is not known. It is thought to work by binding to calcium channels found on nerve cells in the brain and spinal cord. This reduces the release of various neurotransmitters from these nerve cells. The effectiveness of Lyrica (300 or 450 mg/day) for treating fibromyalgia was established by two clinical trials involving 1,800 people. Lower doses (e.g. 50 mg as shown) have been used to treat severe neuropathic | |
| Licence : | Droits gérés |
| Crédit: | Science Photo Library / SciMAT |
| Taille de l’image : | 2844 px × 2053 px |
| Model Release : | Non requis |
| Property Release : | Non requis |
| Restrictions : |
|
Prix pour cette image À partir de 45 €
Produit vendu
(Calendrier, Carte postale, Carte de vœux, Impression sur textile, Packaging etc)
À partir de 45 €
Usage commercial
(Affichage, Annonce presse, Annonce TV, Carte, Digital - hors rés. sociaux, Digital - rés. sociaux etc)
À partir de 45 €
Éditorial
(Digital, Journal, Livre, Livre pratique, Magazine, Télévision etc)
À partir de 60 €
Usage non-commercial
(Digital - hors rés. sociaux, Digital - rés. sociaux etc)
À partir de 120 €